DNMT3A in haematological malignancies
Yang L, Rau R, Goodell M. DNMT3A in haematological malignancies. Nature Reviews Cancer 2015, 15: 152-165. PMID: 25693834, PMCID: PMC5814392, DOI: 10.1038/nrc3895.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsHaematopoietic stem cell differentiationStem cell differentiationStem cell programAberrant DNA methylationDominant negative inhibitorImportant biological relationshipsDifferentiated lineagesHistone methyltransferasesDNA methyltransferasesRegulatory domainDNA methylationMechanistic functionGene expressionHSC progenyMethyltransferase 3AImportant new targetHSC expansionCell differentiationUnique mutational profileDNMT3ACell programHuman HSCsStem cellsEnzymatic activityMutationsDnmt3a loss predisposes murine hematopoietic stem cells to malignant transformation
Mayle A, Yang L, Rodriguez B, Zhou T, Chang E, Curry C, Challen G, Li W, Wheeler D, Rebel V, Goodell M. Dnmt3a loss predisposes murine hematopoietic stem cells to malignant transformation. Blood 2015, 125: 629-638. PMID: 25416277, PMCID: PMC4304108, DOI: 10.1182/blood-2014-08-594648.Peer-Reviewed Original ResearchConceptsHematologic malignanciesDNMT3A mutationsB-cell acute lymphocytic leukemiaAcute lymphocytic leukemiaSpectrum of malignanciesAcute myeloid leukemiaStem cellsPreleukemic phenotypeMyelodysplastic syndromePoor prognosisMyeloid leukemiaLymphocytic leukemiaLymphoid malignanciesMouse modelIrradiated micePrimary myelofibrosisMalignancyPreleukemic cellsLoss of functionDNA methyltransferase 3AMalignant transformationHematopoietic stem cellsMyeloid diseasesLeukemiaLymphoid lineage